Publisher's Synopsis
Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.
It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.
The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.
This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
